Get the Stockscreener App
2.63
2.73%
0.07
Absci Corp stock is traded at $2.63, with a volume of 3.84M.
It is up +2.73% in the last 24 hours and down -27.55% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
See More
Previous Close:
$2.56
Open:
$2.58
24h Volume:
3.84M
Relative Volume:
0.83
Market Cap:
$393.24M
Revenue:
$4.21M
Net Income/Loss:
$-97.67M
P/E Ratio:
-2.828
EPS:
-0.93
Net Cash Flow:
$-70.76M
1W Performance:
-10.24%
1M Performance:
-27.55%
6M Performance:
-46.98%
1Y Performance:
-37.83%
1-Day Range:
$2.56
$2.725
1-Week Range:
$2.49
$2.93
52-Week Range:
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
2.63 | 423.15M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
Absci to Participate in Upcoming Investor Conferences - GlobeNewswire
AI-Powered Drug Discovery Company Absci Announces Major Healthcare Conference Appearances in September - Stock Titan
CRSP, ABSI, IRDM: Cathie Wood Offloads $16.4M of CRISPR Therapeutics Stock, Buys Absci and Iridium - MSN
Is Now a Good Time to Reenter Absci Corporation2025 Breakouts & Breakdowns & Free Fast Entry Momentum Trade Alerts - sundaytimes.kr
Wall Street Zen Downgrades Absci (NASDAQ:ABSI) to Strong Sell - MarketBeat
Absci (NASDAQ:ABSI) Releases Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
Will Absci Corporation continue its uptrendTrade Signal Summary & Intraday High Probability Alerts - Newser
Sentiment analysis tools applied to Absci Corporation2025 Price Targets & Precise Trade Entry Recommendations - Newser
Needham & Company LLC Cuts Absci (NASDAQ:ABSI) Price Target to $8.00 - MarketBeat
Will breakout in Absci Corporation lead to full recoveryMarket Performance Recap & Risk Controlled Stock Alerts - Newser
Absci's Q2 2025 Earnings Call: Unraveling Key Contradictions in Revenue Recognition, Dosing Strategies, and Clinical Timelines - AInvest
Absci Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates - MSN
Absci reports Q2 EPS (24c), consensus (21c) - MSN
ABSI: Needham Maintains 'Buy' Rating, Lowers Target to $8.00 - AInvest
Absci’s Surprising Jump: Analyzing the Latest Market Trends - StocksToTrade
Absci Corporation (NASDAQ:ABSI) Q2 2025 Earnings Call Transcript - Insider Monkey
Needham lowers Absci stock price target to $8 on recent dilution - Investing.com Australia
Absci 2025 Q2 Earnings Worsening Losses Amid Revenue Decline - AInvest
AbSci Corp options imply significant post-earnings price movement. - AInvest
Absci (ABSI): Navigating Near-Term Financial Pressures to Unlock Long-Term AI-Driven Biotech Value - AInvest
Absci Corp (ABSI) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges By GuruFocus - Investing.com Canada
Absci Corporation: Navigating Near-Term Challenges to Unlock Long-Term Growth in AI-Driven Biotech - AInvest
Absci Corporation Reports Q2 2025 Financial Results - TipRanks
Absci Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Absci’s Q2 2025 results disappoint with revenue miss - Investing.com Nigeria
Absci Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Absci earnings missed by $0.03, revenue fell short of estimates - Investing.com
Absci Corp SEC 10-Q Report - TradingView
How to integrate Absci Corporation into portfolio analysis toolsValue Investing Summary and Earnings Outlook - Newser
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results - GlobeNewswire
Absci Strengthens Future: $64M Raise Powers AI Drug Pipeline as Almirall Partnership Grows - Stock Titan
Absci Corp (ABSI) Q2 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Absci ABSI 2025Q2 Earnings Preview Upside Potential with Innovative Product Launches - AInvest
Absci (ABSI) Expected to Announce Earnings on Tuesday - MarketBeat
Historical volatility pattern of Absci Corporation visualized7-Day Equity Return Range Forecast Model - Newser
Absci Corporation (NASDAQ:ABSI) Receives $8.28 Consensus Price Target from Analysts - MarketBeat
Absci Corp expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Absci Corporation (NASDAQ:ABSI) Receives $8.28 Consensus Price Target from Brokerages - Defense World
Absci Corporation Stock (ABSI) Opinions on $50 Million Public Offering and AI Collaboration - Quiver Quantitative
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy? - MSN
Absci, Almirall Expand Collaboration to Include Second Dermatology Target - MarketScreener
Absci (NASDAQ:ABSI) Upgraded to Hold at Wall Street Zen - MarketBeat
AI Drug Discovery Breakthrough: Absci Lands Second Target After Successfully Designing Undruggable Molecule - Stock Titan
Almirall and Absci Corporation Expand Ai Drug Creation Collaboration Adding A Second Dermatology Target - MarketScreener
Almirall selects second target in expanded AI Drug Creation collaboration with Absci. - AInvest
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target - GlobeNewswire
Earnings Preview: Absci Corp to Report Financial Results Post-market on August 12 - 富途牛牛
Absci Corp | 4: Statement of changes in beneficial ownership of securities-Officer Busch Andreas - 富途牛牛
TR | OpenAI4o Maintains Absci Corp(ABSI.US) With Hold Rating, Maintains Target Price $3 - 富途牛牛
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):